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Background: The Tanzanian national HIV care and treatment programme has provided free antiretroviral
therapy (ART) to HIV-positive persons since 2004. ART has been available to participants of the Kisesa open
cohort study since 2005, but data to 2007 showed a slow uptake of ART and a modest impact on mortality.
Additional data from the 2010 HIV serological survey provide an opportunity to update the estimated impact
of ART in this setting.
Methods: The Kisesa Health and Demographic Surveillance Site (HDSS) has collected HIV serological data
and demographic data, including verbal autopsy (VA) interviews since 1994. Serological data to the end of
2010 were used to make two estimates of HIV-attributable mortality, the first among HIV positives using the
difference in mortality between HIV positives and HIV negatives, and the second in the population using
the difference between the observed mortality rate in the whole population and the mortality rate among the
HIV negatives. Four time periods (19941999, 20002004, 20052007, and 20082010) were used and HIV-
attributable mortality estimates were analysed in detail for trends over time. A computer algorithm, InterVA-4,
was applied to VA data to estimate the HIV-attributable mortality for the population, and this was compared
to the estimates from the serological survey data.
Results: Among HIV-positive adults aged 4559 years, high mortality rates were observed across all time
periods in both males and females. In HIV-positive men, the HIV-attributable mortality was 91.6% (95%
confidence interval (CI): 84.6%95.3%) in 20002004 and 86.3% (95% CI: 71.1%93.3%) in 20082010, while
among women, the HIV-attributable mortality was 87.8% (95% CI: 71.1%94.3%) in 20002004 and 85.8%
(95% CI: 59.6%94.4%) in 20082010. In the whole population, using the serological data, the HIV-attributable
mortality among men aged 3044 years decreased from 57.2% (95% CI: 46.9%65.3%) in 20002004 to 36.5%
(95% CI: 18.8%50.1%) in 20082010, while among women the corresponding decrease was from 57.3% (95%
CI: 49.7%63.6%) to 38.7% (95% CI: 27.4%48.2%). The HIV-attributable mortality in the population using
estimates from the InterVA model was lower than that from HIV sero-status data in the period prior to ART,
but slightly higher once ART became available.
Discussion: In the Kisesa HDSS, ART availability corresponds with a decline in adult overall mortality,
although not as large as expected. Using InterVA to estimate HIV-attributable mortality showed smaller
changes in HIV-related mortality following ART availability than the serological results.
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S
ince the first AIDS case was identified in the 1980s,
HIV/AIDS has been a major public health chal-
lenge, particularly in sub-Saharan Africa, where the
burden of the disease is greatest. Prior to the introduction
of free antiretroviral therapy (ART) treatment, the age-
standardised mortality rates among HIV-positive adults
were high, being of the order of 925 times those of the
uninfected (1). In some populations, the probability of
dying between 15 and 60 years of age reached 60% among
men (2). Results from modelling vital registration data
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40% of deaths in South African adults aged 1549 years
were HIV related (3).
The positive effect of ART use on mortality (46),
and support from donor organisations, encouraged the
introduction of free national ART programmes in many
sub-Saharan African countries from 2004. Data from
longitudinal demographic surveillance in several coun-
tries have confirmed the impact of ART on HIV mor-
tality in poor-resource settings. In rural, northern Malawi
there was a 19% decline in AIDS-related mortality amongst
adults aged 1559 within 8 months of ART becoming
available (7), and a 68% decline over the 5 years from
20042009 (8). In northern KwaZulu-Natal, South Africa,
HIV-related mortality in adults aged 2549 years was
reduced by 22% in women and 29% in men between
20022003 and 20042006 following the introduction of
ART in 2004 (9). In South-west Uganda, there was a 19%
decline in the HIV population-attributable fraction of
mortality among adults aged 1559 in the 5-year period
after ART introduction in 2004 (10).
This study aims to assess the long-term impact of
ARTon HIV/AIDS mortality in Kisesa, Tanzania. In this
observational study, care and treatment services were
provided by local health facilities in line with national
policies. While residents of Kisesa had initial access to
ART in 2005, it was only available at a referral hospital
20 km away. Referrals from the local voluntary counselling
and testing (VCT) to the regional hospitals in Mwanza
were not well organised. In addition, travel and other
logistics were difficult for the Kisesa residents. By 2007,
only 3% of adults in need of treatment were receiving
ART (11) but even at this low level of coverage there was
evidence to suggest ART was having an impact on adult
mortality (12). To improve the situation, the Kisesa study
group (TAZAMA study) facilitated referrals to the
hospital to improve uptake of ART in the study area
during this ART introduction period. However from
2008, ART became available at a local clinic in Kisesa
which allowed easier access and improved uptake of
ART, with a corresponding increase in the proportion of
adults in need receiving treatment (unpublished data). In
this study, data from the serological surveys and demo-
graphic follow-up until 2010 are used to examine trends
in HIV-attributable mortality, both among HIV-positive
adults and in the whole population, over time.
Methods
The Kisesa open cohort study consists of six villages in
Mwanza region in Tanzania. In 2010, the total popula-
tion was approximately 30,000. In the period 19941998,
life expectancy was 4344 years, and approximately
50% of the population were younger than age 15 (13).
Biannual health demographic surveillance system (HDSS)
rounds since 1994 have measured births, deaths, and migra-
tion in the resident population, with mortality among
adults aged 1559 years estimated at 39% in 1994, and
22% in 2009 (14). Annual adult external migration (out of
the Kisesa cohort) has been shown to be 10% in males
and 12% in females in 19941998 (15), and around
8% among both male and female adults in 2012 (16)
(unpublished thesis). Verbal autopsies (VAs) have been
conducted to track the leading causes of death (13), in
which the main care giver or the most reliable informant
available is interviewed to capture the signs and symp-
toms that the deceased had in the time leading to their
death (17). The current VA questionnaire is taken from
the recommended WHO tool (18), although previous
versions were very similar, and included the same ques-
tions on signs and symptoms required for the ascertain-
ment of cause of death.
Since 1994, six serological surveys have been carried
out to measure HIV prevalence and incidence in the
cohort population; the first was restricted to adults aged
between 15 and 50 years of age while subsequent sero-
logical surveys were conducted amongst all adults aged
15 years and above (19, 20). The serological surveys were
done at 2- to 3-year intervals and the first four were done
in 1994/1995, 1996/1997, 1999/2000, and 2003/2004 (20).
The other two were done in 2006/2007 and in 2010. They
included questionnaire-based interviews and thereafter,
consenting adults provided a finger prick blood sample,
which was tested for HIV at the National Institute for
Medical Research laboratory in Mwanza (12). Almost all
of the respondents aged 15 who got interviewed also
got tested for HIV. In the first four serological surveys, of
the 28,591 interviews done, 28,523 interviewees got tested
(20). Attendance rates were between 61 and 86% across
the sexes and surveys. Non-attendance is mainly due to
absence from home during the survey and not rejecting to
get tested for HIV (20).
HIV prevalence in Kisesa HDSS increased steadily
from about 6% in 19941995 until its peak at about 8.3%
in 20002001 (20). It then went down to 7.6% in 2004
and then 7.1% in 2007 (21). By 2011, the prevalence was
6% (22).
Statistical methods
For this analysis, adult person-years of residence were
assessed from entry into the HDSS either at age 15 years,
through in-migration, or since the start of the HDSS in
1994, until their exit due to out-migration, death or cen-
soring at the time of the latest HDSS survey. Returning
migrants (the individuals re-entering the study following
out-migration) contribute person-years only for the time
they were actually resident in the study site. Person-years
were stratified by sex and further by age group, and years
related to ART rollout. Age was stratified into three age
groups (1529, 3044 and 4559 years, respectively).
Person-years of exposure were also stratified into different
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HIV status unknown. HIV-negative person-years were
obtained by summing the time between successive HIV-
negative tests, up to 5 years following the last recorded
HIV-negative test, and the half the period between a
negative test and a subsequent positive test in which the
sero-conversion interval is less than 5 years. HIV-positive
person-years were obtained from the time following an
HIV-positive test. HIV unknown person-years were ob-
tained from summing the time observed for those never
tested or not yet tested (i.e. before first test, whether or
not that first test was positive or negative) and the period
more than 5 years following the last negative test.
Mortality rates were obtained by dividing the number
of deaths by the person-years at risk, and 95% confidence
intervals (95% CI) obtained from the normal approxima-
tion to the log rate (23).
Analysis was carried out separately based on the avail-
ability of ART, with four time periods identified as fol-
lows: 1) More than 5 years before ART (i.e. no treatment
available) from 1994 to 2000; 2) 5 years leading to the
introduction of ART (20002004); 3) a 3-year roll-out
phase immediately following the introduction of ART
when ART was assumed to be only partially available
(20052007); and 4) a phase when ART was widely and
locally available (20082010).
Mortality rates, Mx, were calculated by dividing the
deaths, Dx, by the person-years of residence, Lx, for each
age and sex group (designated as x in the equation),
Mx ¼
Dx
Lx and are expressed as mortality per 1,000 person-
years (1,000 pyrs).
HIV-attributable fraction among HIV-positive adults
Within each period, mortality rates were calculated
separately among the HIV positives (MHIVþ
x ) and HIV
negatives (MHIV 
x ). The HIV-attributable mortality among
the positives was calculated as the excess mortality
among the HIV positives after subtracting the expected
non-AIDS mortality among the HIV positives, as given
by:
M
HIVþattrib
x ¼
DHIVþattrib
x
LHIVþ
x
¼ M
HIVþ
x   M
HIV 
x ;
where MHIVþattrib
x is the age-specific mortality due to HIV
among the HIV positive, DHIVþattrib
x are the deaths due to
HIV among the HIV positive, LHIVþ
x are the person-years
lived by the HIV positives, MHIVþ
x is the overall mortality
among the HIV positives and MHIV 
x is the mortality
among the HIV negatives. HIV-attributable fractions
among the HIV positives were then calculated by dividing
MHIVþattrib
x by MHIVþ
x .
HIV-attributable fraction among the whole
population
The HIV-attributable mortality in the population was
calculated as:
M
PopAttrib
x ¼ M
TotalPop
x   M
HIV 
x ;
where MPopAttrib
x is the age-specific mortality rate due to
HIV in the population and MTotalPop
x is the mortality rate
in the total population. Similarly, HIV-attributable mor-
tality fractions in the entire population were calculated by
dividing MPopAttrib
x by MTotalPop
x .
The InterVA4 algorithm
The InterVA4 algorithm is a probability-based model for
assigning causes of death on the basis of verbal autopsy
(VA) interview reports from the main caregivers of the
deceased (24). In this study, it was used to assign the
cause of deaths occurring in the study population for
the period 1994 to 2010. The InterVA4 model takes res-
ponses from a VA interview and uses these inputs to
determine probabilistic causes of deaths.
InterVA4 is not intended to diagnose the cause of death
for an individual case, but the probabilities of any cause of
death can be added up across the population to give the
expected total number of deaths for that cause. In this
study, the InterVA algorithm was applied to all deaths
where a VA had been performed in the Kisesa cohort in
order to estimate the probability of HIV being the cause
of the death. These probabilities were added up over all
deaths to obtain the number of HIV-related deaths and
the HIV-attributable mortality in the population. The
population HIV-attributable mortality fraction from the
InterVA4 model was compared to the HIV-attributable
mortality fraction from the serological data in Kisesa.
Table 1. Number of subjects, person-years and deaths by ART phase in adults aged 15 years and above in the HDSS population
ART phase Number of subjects Person-years Deaths Mortality rate per 1,000 pyrs 95% CI
5 years before ART (19942000) 23,316 60,057 783 13.0 12.014.0
05 years before ART (20002004) 26,031 63,248 780 12.3 11.513.1
During ART introduction (20052007) 22,253 48,309 523 10.8 9.811.8
After ART became available (20082010) 22,387 46,274 370 8.0 7.28.8
ARTantiretroviral therapy; CIconfidence interval; HDSSHealth and Demographic Surveillance Site; pyrs=person-years.
Impact of ART on adult mortality in rural Tanzania
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Characteristics of data
Table1showsthecrudemortality ratesamong adultsaged
15 years and over by time period. Overall crude mortality
in the adult population has gone down from 13 deaths per
1,000 person-years in the period at least 5 years before
ART, to 12 deaths per 1,000 person-years in the 5-year
period leading to the introduction of ART, to eight deaths
per 1,000 person-years during the period of widespread
availability of ART. There was strong evidence for a
declineinmortalityratesbetweentheperiod5yearsbefore
ART introduction and the period when ART became
widely available (HR: 0.61, 95% CI: 0.540.69, pB0.000).
Age-specific mortality rates by HIV status and ART
availability
Tables 2 and 3, show person-years, deaths and mortality
rates stratified by age, HIV status and ART availability
for males and females, respectively. Mortality among
the HIV negatives was generally lower than among HIV
positives for both sexes and all age groups across the four
time periods considered. The levels of mortality for those
with unknown HIV status were generally in between
those of the HIV negatives and those of the HIV posi-
tives. The mortality rates among the HIV positives
declined over time following the introduction of ART,
while the HIV-negative mortality rates of both males and
females fluctuated over time without a clearly defined
trend. In each time period and HIV status group, mor-
tality increased by age, except in the period 5 or more
years before introduction of ART during which it was
highest in the 3044 years age group for HIV-positive
males and in the period of wide ART availability where
for females it was highest in the 1529 age group. The
decline in mortality is clearer and more consistent in the
HIV-positive women compared to men. However, the CI
are overlapping and wide indicating high uncertainty
surrounding the magnitude of the decline in the mortality
reported.
HIV-attributable mortality in the Kisesa HDSS
HIV-attributable mortality estimates are presented in
Tables 4 and 5 for males and females, respectively. In
HIV-positive people of both sexes, and across all of the
periods, around 90% of the deaths among those aged
1559 years of age are due to HIV. There was little change
in this proportion in the periods after the introduction
of ART, suggesting that mortality attributable to HIV
among HIV-positive people is still very high. The HIV-
attributable mortality in the entire population appears to
decline over time. In the periods before ART, more than
40% of the deaths in both males and females aged 1544
years of age were attributable to HIV. After the introduc-
tion of ART, the proportion of mortality attributable to
HIV in the 1544 year age groups reduced to less than
40% among the males, although among females the
pattern was less clear.
Table 2. Age-speciﬁc person-years, deaths and mortality rates per 1000 person-years by HIV status and ART availability
observed in Kisesa open cohort among male adults aged 1559 in the period 19942010
HIV negative HIV positive HIV status unknown
Age interval
Person-
years Deaths
Mortality rate
(95% CI)
Person-
years Deaths
Mortality rate
(95% CI)
Person-
years Deaths
Mortality rate
(95% CI)
5 years before ART (19941999)
1529 7618.5 21 2.8 (1.84.2) 170.5 7 41.1 (19.686.1) 7081.8 38 5.4 (3.97.4)
3044 4015.3 26 6.5 (4.49.5) 260.3 34 130.6 (93.3182.8) 3848.8 57 14.8 (11.419.2)
4559 530.3 8 15.1 (7.530.2) 44.6 5 112.0 (46.6269.1) 3495.6 69 19.7 (15.625.0)
05 years before ART (20002004)
1529 7382.8 9 1.2 (0.62.3) 252.9 8 31.6 (15.863.3) 7816.7 44 5.6 (4.27.6)
3044 4335.5 24 5.5 (3.78.3) 354.7 28 78.9 (54.5114.3) 4084.3 61 14.9 (11.619.2)
4559 2115.0 29 13.7 (9.519.7) 133.1 22 165.2 (108.8251.0) 1843.5 27 14.6 (10.021.4)
ART introduction (20052007)
1529 5723.7 16 2.8 (1.84.6) 145.1 6 41.3 (18.692.0) 5681.6 20 3.5 (2.35.5)
3044 3061.3 27 8.8 (6.012.9) 277.5 21 75.7 (49.3116.1) 3417.5 29 8.5 (5.912.2)
4559 1789.3 27 15.1 (10.322) 112.0 10 89.3 (48.0166.0) 1457.0 23 15.8 (10.523.8)
ART available (20082010)
1529 4558.6 15 3.3 (2.05.5) 85.0 3 35.3 (11.4109.5) 6182.4 24 3.9 (2.65.8)
3044 2075.4 4 1.9 (0.75.1) 181.3 8 44.1 (22.188.3) 4303.0 23 5.3 (3.68.0)
4559 1420.1 8 5.6 (2.811.3) 141.7 9 63.5 (33.1122.1) 1679.6 24 14.3 (9.621.3)
ARTantiretroviral therapy; CIconfidence interval.
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observed in Kisesa open cohort among female adults aged 1559 in the period 19942010
HIV negative HIV positive HIV status unknown
Age interval
Person-
years Deaths
Mortality rate
(95% CI)
Person-
years Deaths
Mortality rate
(95% CI)
Person-
years Deaths
Mortality rate
(95% CI)
5 years before ART (19941999)
1529 6671.8 15 2.3 (1.43.7) 408.5 21 51.4 (33.578.8) 7787.0 46 5.9 (4.47.9)
3044 5153.5 19 3.7 (2.45.8) 305.7 31 101.4 (71.3144.2) 3081.6 45 14.6 (10.919.6)
4559 632.6 3 4.7 (1.514.7) 18.5 3 161.9 (52.2501.9) 3503.2 51 14.6 (11.119.2)
05 years before ART (20002004)
1529 6536.0 19 2.9 (1.94.6) 407.9 17 41.7 (25.967.0) 8418.8 43 5.1 (3.86.9)
3044 6166.7 34 5.5 (3.97.7) 482.6 39 80.8 (59.0110.6) 2766.0 42 15.2 (11.220.5)
4559 3139.6 35 11.1 (8.015.5) 106.1 10 94.3 (50.7175.2) 1251.6 17 13.6 (8.421.8)
ART introduction (20052007)
1529 4958.0 12 2.4 (1.44.3) 217.8 11 50.5 (28.091.2) 6034.2 22 3.6 (2.45.5)
3044 4699.5 19 4.0 (2.66.3) 429.9 18 41.9 (26.466.5) 2212.6 19 8.6 (5.513.5)
4559 2619.0 20 7.6 (4.911.8) 116.7 10 85.7 (46.1159.3) 948.4 10 10.5 (5.719.6)
ART available (20082010)
1529 4091.1 6 1.5 (0.73.3) 155.0 5 32.3 (13.477.5) 6946.9 17 2.4 (1.53.9)
3044 3422.1 9 2.6 (1.45.1) 441.5 10 22.6 (12.242.1) 2977.2 19 6.4 (4.110.0)
4559 2261.4 7 3.1 (1.56.5) 144.7 3 20.7 (6.764.3) 1216.7 16 13.1 (8.121.5)
ARTantiretroviral therapy; CIconfidence interval.
Table 4. HIV-attributable mortality for males aged 1559 in Kisesa open cohort from serological data and InterVA model,
19942010
Using sero-status data Using InterVA4
Age interval *Deaths
HIV-attributable mortality
fractions among the HIV-
positive deaths (95% CI)
HIV-attributable mortality
fractions in the entire
population (95% CI) **Deaths
HIV-deaths
assigned by
InterVA4
% deaths
attributable to HIV
using InterVA4
5 years before ART (19941999)
1529 66 94.1 (83.597.6) 41.1 (28.151.6) 64 19 29.7
3044 117 95.3 (91.997.3) 56.2 (46.264.3) 109 39 35.8
4559 82 85.0 (30.296.2) 27.6 (19.755.5) 71 12 16.9
05 years before ART (20002004)
1529 61 96.1 (88.598.7) 68.5 (53.578.4) 36 8 22.2
3044 113 93.0 (87.596.1) 57.2 (46.965.3) 52 11 21.2
4559 78 91.6 (84.695.3) 26.2 (15.435.6) 44 7 15.9
ART introduction (20052007)
1529 42 91.5 (50.498.0) 11.8 (12.530.2) 34 6 17.6
3044 77 79.8 (41.592.3) 12.7 (4.927.1) 64 14 21.9
4559 60 87.9 (61.195.7) 13.5 (3.027.0) 56 11 19.6
ART available (20082010)
1529 42 91.4 (74.696.6) 14.2 (1.225.4) 27 8 29.6
3044 35 93.2 (86.596.6) 36.5 (18.850.1) 29 16 55.2
4559 41 86.3 (71.193.3) 35.8 (22.746.5) 29 5 17.2
Of the *814 male deaths among adults aged 1559. **615 (76%) had VAs thus the difference in the number of deaths with a sero-status
and those with a corresponding VA. ARTantiretroviral therapy; CIconfidence interval; VAsverbal autopsies.
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Table 4 (males) and 5 (females) show the population
HIV-attributable mortality from the InterVA4 model
compared to the population HIV-attributable mortality
from the serological data.
The InterVA-4 model gave higher HIV-attributable
mortality among the females compared to the males. The
exception is the period of ART introduction in which
the proportions of deaths attributable to HIV are higher
among the males than the females in all age groups.
Comparison of the InterVA-4 estimates to those obtained
from serological data show that for the pre-ART period,
InterVA-4 provides lower estimates of mortality attribu-
table to HIV in the population. However, in the period of
ART introduction and the subsequent period of ART
availability, the InterVA model tended to overestimate
the population-level HIV-attributable mortality in both
males and females.
Discussion
This paper uses age-specific mortality rates and HIV-
attributable mortality fractions to assess the impact of
ART availability on adult mortality in the Kisesa HDSS.
The results show that the availability of ART to HIV-
positive participants has so far yielded a slow decline in
adult mortality, six years after it was introduced in 2005.
However, the coverage of ART in Kisesa was very low,
estimated at 3% for the first 3 years after it was introduced
(11, 12). The availability of ART has improved over time,
but the impact on population-level mortality may still
take some time to observe. Although the methods used in
this paper (population attributable fractions among the
HIV positives and in the entire population) are different
from the exponential regression and hazard rate ratios
used previously in this setting (12), the results from these
two studies broadly agree in showing that the impact of
ART is modest, even with the additional data from the
most recently completed serological survey in 2010.
This decline in mortality in Kisesa is less than that
reported in other sub-Saharan countries where ART
has been introduced, including sites collecting similar
community-level serological and demographic data in
Uganda (10), South Africa (9) and Malawi (8, 25). Results
from the Karonga Prevention Study (KPS), which is a
similar mixture of semi-urban and rural settings as the
Kisesa open cohort, showed a mortality decline of 21%
(95% CI: 236%) after ART introduction (between 2004
05 and 200809), especially when ART became available
within the KPS area (8). These differences are likely to
be partially explained by different levels of uptake of
HIV testing services. For example, in Kisesa, VCTuptake
among HIV-positive people during the serological surveys
Table 5. HIV-attributable mortality for females aged 1559 in Kisesa open cohort from serological data and InterVA model,
19942010
Using sero-status data Using InterVA4
Age interval *Deaths
HIV-attributable mortality
fractions among the HIV-
positive deaths (95% CI)
HIV-attributable mortality
fractions in the entire
population (95% CI) **Deaths
HIV deaths
assigned by
InterVA4
% deaths
attributable to HIV
using InterVA4
5 year before ART (19941999)
1529 82 95.4 (90.597.8) 58.2 (44.668.3) 78 39 50.0
3044 95 96.2 (93.098.0) 65.3 (55.972.7) 83 43 51.8
4559 57 97.0 (77.499.6) 61.8 (14.382.0) 57 10 17.5
05 year before ART (20002004)
1529 79 93.2 (86.396.6) 44.9 (30.756.1) 51 16 31.4
3044 115 93.5 (89.396.1) 57.3 (49.763.6) 61 30 49.2
4559 62 87.8 (71.194.3) 19.1 (12.025.5) 35 4 11.4
ART introduction (20052007)
1529 45 92.0 (50.698.3) 32.4 (2.852.1) 41 13 31.7
3044 56 93.2 (80.097.7) 57.9 (42.069.2) 50 14 28.0
4559 40 93.9 (81.497.8) 37.3 (24.048.0) 36 8 22.2
ART available (20082010)
1529 28 96.5 (91.498.6) 44.9 (25.259.1) 19 8 42.1
3044 38 85.8 (72.892.6) 38.7 (27.448.2) 28 15 53.6
4559 26 85.8 (59.694.4) 39.5 (28.148.9) 17 5 29.4
Of the *723 female deaths among adults aged 1559. **556 (77%) had VAs thus the difference in the number of deaths with a sero-status
and those with a corresponding VA. ARTantiretroviral therapy; CIconfidence interval; VAsverbal autopsies.
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mately 25% in 20062007 (26). Much higher levels of
knowledge of HIV status have been reported in Malawi
(95%) in 20072008 where opt-out testing and door-
to-door delivery of test results has been offered during
serological surveys. Similarly, in Masaka in Uganda,
where HIV testing is offered at the household during the
annual survey rounds, 56% of HIV-positive adults knew
their status in 2008 (11). It is most likely that the impact
of ART on mortality will be realised only when wider
coverage of VCT and ART are achieved in Kisesa.
Measuring HIV-attributable mortality is important
for the evaluation of ART delivery programmes (27).
However, it can only be properly measured with good
serological data from a representative population-based
cohort, and there are few such cohorts in most countries
affected by the HIV epidemic. Studies on HIV-positive
patients attending clinics can provide estimates of the
impact of ART on mortality (28), but do not capture the
impact of those who do not know their HIV status, or
who have not been assessed for eligibility for ART. Other
studies have shown that monitoring burial grounds can
estimate the impact of ART on HIV-related mortality,
although this does depend on the local culture surround-
ing death, and the proportion of people using public
cemeteries (29).
We compared the population HIV-attributable frac-
tions directly calculated from the sero-status of those who
died, and the HIV-attributable mortality from VA where
the cause of death had been assigned using the InterVA-4
algorithm. The comparison showed that in the pre-ART
period, InterVA tended to provide lower estimates of the
contribution of HIV to mortality, but in the period when
ART was available, InterVA overestimated the contribu-
tion of HIV to mortality. Two other studies have used
VA data, one in Kenya and the other one in Ethiopia, com-
paring the InterVA assessment with the causes of death
assigned by physicians (30, 31). In the Kenyan study, HIV-
attributable mortality was underestimated by InterVA
compared to the physician assignment, but gave similar
HIV-attributable mortality fractions when tuberculosis
and HIV/AIDS were combined (30). The Ethiopian study
on the other hand compared HIV-attributable deaths
as assigned by InterVA and those from known hospital
diagnosis and HIV status of the deceased (31). The
results from this study seem to also suggest that InterVA
performs better when HIV and TB are combined. In
Kisesa, combining TB and HIV/AIDS-related deaths from
InterVA-4 did not alter the results substantially as a
relatively small proportion of deaths were assigned to
TB (data not shown). On the other hand, a study in
Agincourt, South Africa suggests broadly similar HIV-
attributable mortality trends over time between InterVA
assessment and physician assignment of cause of death (32).
Further work may be needed to confirm the usefulness
of the InterVA algorithm in assessing HIV-attributable
mortality in sub-Saharan Africa.
There are some limitations related to this study. The
numbers of deaths used in the calculation of age-specific
HIV-attributable mortality fractions are quite small, so
the results may be due to random variation and should
therefore be interpreted with caution. We did not adjust
for potential confounders such as socio-economic status,
which may affect the relationship between availability of
ART and mortality. We also did not take into considera-
tion the selection effect that migration may bring since
those who migrate out are not followed-up to observe
their mortality. However, we have no significant reasons
to think that those who migrate both in and out of the
study area would exhibit different mortality patterns to
those of their non-moving counterparts. Participants who
tested HIV negative and either had no subsequent test, or
tested positive in the subsequent test done more than 5
years after the negative test, were assumed to be HIV
negative for up to 5 years. They were then classified as
unknown until the date of testing positive. This assump-
tion was made after observing that 95% of those testing
HIV negative in a particular round of serological survey
remained negative in the ensuing 5 years. We also did
sensitivity analysis (data not shown) assuming 2 and 10
years cut-offs for changing classifications of the HIV
negative into the unknown group. We did not observe any
significant changes in the mortality, therefore we think
that the cut-off at 5 years in not unreasonable.
In conclusion, the current study has confirmed a
decline in HIV-attributable mortality among HIV posi-
tives and all adults in the study population. The decline is
not as pronounced as has been experienced in similar
study populations in Uganda, Malawi and South Africa,
even after 3 years of availability of ART at a clinic in
Kisesa, suggesting that greater efforts are needed to
improve VCT uptake and treatment initiation for those
needing ART in this setting. Analysis of the retention
rates for those on ART should be considered in order to
confirm the duration of time that individuals starting
ART are remaining on treatment.
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